Display Settings:

Format

Send to:

Choose Destination
Head Neck. 2013 Jan;35(1):76-85. doi: 10.1002/hed.22924. Epub 2012 Jan 24.

Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma.

Author information

  • 1Department of Internal Medicine, UMDNJ-Robert Wood Johnson Medical School, Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.

Abstract

BACKGROUND:

We postulated that disruptions of the canonical transforming growth factor-beta (TGF-β)/Smad signaling pathway might contribute to the development of head and neck squamous cell carcinoma (HNSCC).

METHODS:

A cohort of 798 HNSCC tumor samples from 346 patients were analyzed by immunohistochemistry (IHC) to define the pattern of expression of (phospho)Smad2, (phospho)Smad3, and Smad4.

RESULTS:

We found that 19%, 40%, and 12% of HNSCC specimens failed to express pSmad2, pSmad3, or Smad4, respectively. Loss of Smad2/3 activation was observed in 8.5% of specimens. In addition, 4% of specimens failed to express only Smad4. Moreover, patients with pSmad2/3-negative tumors had a significantly better overall survival than that of those whose tumors expressed activated Smad2/3. In contrast, loss of Smad4 expression did not have prognostic significance.

CONCLUSION:

Our results indicate that HNSCC in which Smad2/3 are inactivated or in which Smad4 expression is lost represent 2 distinct tumor subtypes with different clinical outcomes.

Copyright © 2012 Wiley Periodicals, Inc.

PMID:
22275186
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk